183 related articles for article (PubMed ID: 38675174)
1. GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics.
Obeid K; Kanellopoulos P; Abouzayed A; Mattsson A; Tolmachev V; Nock BA; Maina T; Orlova A
Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675174
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics.
Abouzayed A; Kanellopoulos P; Gorislav A; Tolmachev V; Maina T; Nock BA; Orlova A
Biomolecules; 2023 Jul; 13(7):. PubMed ID: 37509170
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology.
Kanellopoulos P; Mattsson A; Abouzayed A; Obeid K; Nock BA; Tolmachev V; Maina T; Orlova A
EJNMMI Radiopharm Chem; 2024 Feb; 9(1):13. PubMed ID: 38366299
[TBL] [Abstract][Full Text] [Related]
4. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
Mitran B; Varasteh Z; Selvaraju RK; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Rosenström U; Orlova A
Int J Oncol; 2016 May; 48(5):2124-34. PubMed ID: 26983776
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of
Abouzayed A; Rinne SS; Sabahnoo H; Sörensen J; Chernov V; Tolmachev V; Orlova A
Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33573232
[TBL] [Abstract][Full Text] [Related]
6. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist
Mitran B; Rinne SS; Konijnenberg MW; Maina T; Nock BA; Altai M; Vorobyeva A; Larhed M; Tolmachev V; de Jong M; Rosenström U; Orlova A
Int J Cancer; 2019 Dec; 145(12):3347-3358. PubMed ID: 31077356
[TBL] [Abstract][Full Text] [Related]
8. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
9. Two Novel [
Kanellopoulos P; Bezverkhniaia E; Abouzayed A; Rosenström U; Tolmachev V; Orlova A
ACS Omega; 2024 Apr; 9(16):18608-18616. PubMed ID: 38680331
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging.
Varasteh Z; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Sandström M; Selvaraju RK; Malmberg J; Tolmachev V; Orlova A
Bioconjug Chem; 2013 Jul; 24(7):1144-53. PubMed ID: 23763444
[TBL] [Abstract][Full Text] [Related]
11. Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN
Cheng S; Lang L; Wang Z; Jacobson O; Yung B; Zhu G; Gu D; Ma Y; Zhu X; Niu G; Chen X
Bioconjug Chem; 2018 Feb; 29(2):410-419. PubMed ID: 29254329
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging.
Varasteh Z; Aberg O; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Antoni G; Sandström M; Tolmachev V; Orlova A
PLoS One; 2013; 8(12):e81932. PubMed ID: 24312607
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer.
Baun C; Mitran B; Rinne SS; Dam JH; Olsen BB; Tolmachev V; Orlova A; Thisgaard H
Molecules; 2020 Dec; 25(24):. PubMed ID: 33352838
[TBL] [Abstract][Full Text] [Related]
14.
Rinne SS; Abouzayed A; Gagnon K; Tolmachev V; Orlova A
Sci Rep; 2021 Feb; 11(1):3631. PubMed ID: 33574368
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer.
Abouzayed A; Tano H; Nagy Á; Rinne SS; Wadeea F; Kumar S; Westerlund K; Tolmachev V; Eriksson Karlström A; Orlova A
Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33081166
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
